Paraneoplastic bilateral vocal cord paralysis in a patient with anti-Hu syndrome after receiving nivolumab: Case report and literature review

IF 2.5 4区医学 Q3 IMMUNOLOGY

Journal of neuroimmunology Pub Date : 2025-06-28 DOI:10.1016/j.jneuroim.2025.578679

Seyda Erdoğan , Elif Peker , Ahmet Demirkazık , Nursel Aydın , Canan Yücesan

{"title":"Paraneoplastic bilateral vocal cord paralysis in a patient with anti-Hu syndrome after receiving nivolumab: Case report and literature review","authors":"Seyda Erdoğan , Elif Peker , Ahmet Demirkazık , Nursel Aydın , Canan Yücesan","doi":"10.1016/j.jneuroim.2025.578679","DOIUrl":null,"url":null,"abstract":"<div><div>Bilateral vocal cord paralysis (BVCP), a life-threatening condition often necessitating tracheotomy, has been infrequently reported as a paraneoplastic manifestation. We present the case of a 75-year-old male with small cell lung cancer who experienced distinct episodes of paraneoplastic neurological syndromes. The initial episode, occurring concomitant with the diagnosis of cancer and initiation of chemotherapy, was characterized by epileptic seizures and ataxia, which resolved following treatment with immunotherapy. The subsequent episode, presenting as BVCP, developed after the fourth dose of nivolumab as part of the patient's paraneoplastic syndrome. Brain magnetic resonance imaging revealed bilateral hyperintense lesions in the anterior medulla oblongata on T2/FLAIR-weighted sequences. To the best of our knowledge, this represents the first documented case of paraneoplastic BVCP associated with bilateral bulbar lesions, potentially triggered by immune checkpoint inhibitor therapy.</div></div>","PeriodicalId":16671,"journal":{"name":"Journal of neuroimmunology","volume":"406 ","pages":"Article 578679"},"PeriodicalIF":2.5000,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neuroimmunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165572825001602","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Bilateral vocal cord paralysis (BVCP), a life-threatening condition often necessitating tracheotomy, has been infrequently reported as a paraneoplastic manifestation. We present the case of a 75-year-old male with small cell lung cancer who experienced distinct episodes of paraneoplastic neurological syndromes. The initial episode, occurring concomitant with the diagnosis of cancer and initiation of chemotherapy, was characterized by epileptic seizures and ataxia, which resolved following treatment with immunotherapy. The subsequent episode, presenting as BVCP, developed after the fourth dose of nivolumab as part of the patient's paraneoplastic syndrome. Brain magnetic resonance imaging revealed bilateral hyperintense lesions in the anterior medulla oblongata on T2/FLAIR-weighted sequences. To the best of our knowledge, this represents the first documented case of paraneoplastic BVCP associated with bilateral bulbar lesions, potentially triggered by immune checkpoint inhibitor therapy.

查看原文本刊更多论文

抗胡综合征患者接受纳武单抗后的副肿瘤性双侧声带麻痹1例：病例报告及文献复习

双侧声带麻痹（BVCP）是一种危及生命的疾病，通常需要气管切开术，但很少被报道为副肿瘤表现。我们提出的情况下，一个75岁的男性小细胞肺癌谁经历了副肿瘤神经综合征的明显发作。最初的发作伴随着癌症的诊断和化疗的开始，以癫痫发作和共济失调为特征，在免疫治疗后消退。随后的发作，表现为BVCP，在第四次纳武单抗治疗后出现，作为患者副肿瘤综合征的一部分。脑磁共振成像在T2/ flair加权序列上显示双侧延髓前部高强度病变。据我们所知，这是第一例与双侧球病变相关的副肿瘤BVCP，可能由免疫检查点抑制剂治疗引发。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of neuroimmunology 医学-免疫学

CiteScore

6.10

自引率

3.00%

发文量

154

审稿时长

37 days

期刊介绍： The Journal of Neuroimmunology affords a forum for the publication of works applying immunologic methodology to the furtherance of the neurological sciences. Studies on all branches of the neurosciences, particularly fundamental and applied neurobiology, neurology, neuropathology, neurochemistry, neurovirology, neuroendocrinology, neuromuscular research, neuropharmacology and psychology, which involve either immunologic methodology (e.g. immunocytochemistry) or fundamental immunology (e.g. antibody and lymphocyte assays), are considered for publication.